Rumors Of Big Pharma Sales Force Cuts Could Boost Smaller Contracts For Ventiv
This article was originally published in The Pink Sheet Daily
Executive Summary
Small and mid-sized companies are more likely to seek contractors rather than enter into partnering deals with big pharma companies, Ventiv CEO Broshy says. Strong demand for CSO services is likely to continue among smaller companies as they make up a larger proportion of approved NDA holders.
You may also be interested in...
PDI Reducing Reliance On Top Pharma Clients
Contract sales organization’s top four clients – AstraZeneca, GSK, Novartis and Sanofi-Aventis – will represent 59% of 2005 revenue, versus 81% in 2004, PDI says. Contracts with three of the four companies have been renewed.
PDI Reducing Reliance On Top Pharma Clients
Contract sales organization’s top four clients – AstraZeneca, GSK, Novartis and Sanofi-Aventis – will represent 59% of 2005 revenue, versus 81% in 2004, PDI says. Contracts with three of the four companies have been renewed.
GSK Will Cut Sales Force And Reinvest In R&D If Pfizer Acts First
Company would “welcome” a decision by Pfizer to cut back its sales force, CEO Garnier declares. Analyst reports have ignited market speculation that Pfizer is ready to retool its sales and marketing infrastructure.